Drugs / ABBV-916
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05291234 | Aug 2022 → Nov 2025 | Alzheimer disease | AbbVie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-916 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05291234 ↗ |
| Route | Intravenous | “Intravenous administration” NCT05291234 ↗ |